Approved for VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).. The mechanism of action of VOWST has not been established. Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels, openFDA FAERS, and CMS NADAC pricing.
Loading full data from Know Your Drugs Institute…